Novel Antiherpes Therapy
Anviro Therapeutics (Anviro) is a broad-spectrum antiviral company that is developing treatments for some of the world?s most problematic infectious diseases, including pox viruses and herpes viruses. Our lead program is based on technology discovered by researchers at Brigham Young University (BYU). This compound, designated KPB-100, was found to have powerful antiviral properties, and efficacy across a wide range of viruses in the herpes and pox virus families. In April of 2015, Anviro licensed this technology from BYU and are in the process of medicinal optimization and animal model validation. KPB-100 has demonstrated low toxicity and a stable shelf-life in initial assays. In vitro and in vivo assays have shown promise for KPB-100 as a topical treatment for multiple DNA-viruses, including: ? Wildtype and mutant HSV-1 and HSV-2 ? Herpes zoster (shingles) ? Progressive vaccinia ? Adverse effects of smallpox vaccination.